Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02954991
Title Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications

lung non-small cell carcinoma

Therapies

Nivolumab + Sitravatinib

Mocetinostat + Nivolumab

Glesatinib + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.